CASI Pharmaceuticals Files August 2024 6-K Report
Ticker: CASIF · Form: 6-K · Filed: Aug 16, 2024 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, corporate-update
TL;DR
CASI Pharma filed its August 6-K, standard update from Beijing.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 16, 2024, reporting for the month of August 2024. The filing is from their principal executive office in Beijing, People's Republic of China. The company was formerly known as CASI Pharmaceuticals Holdings, Inc. until a name change on January 18, 2023.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding CASI Pharmaceuticals' ongoing operations and corporate status.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that typically contains standard corporate information and does not indicate significant new risks.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- August 16, 2024 (date) — Filing Date
- Beijing, People's Republic of China (location) — Principal Executive Office
- CASI Pharmaceuticals Holdings, Inc. (company) — Former Company Name
- January 18, 2023 (date) — Date of Name Change
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the registrant makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
When was CASI Pharmaceuticals, Inc. previously known by another name?
CASI Pharmaceuticals, Inc. was formerly known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023.
Where is CASI Pharmaceuticals, Inc.'s principal executive office located?
The principal executive office of CASI Pharmaceuticals, Inc. is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
What is the SEC file number for CASI Pharmaceuticals, Inc.?
The SEC file number for CASI Pharmaceuticals, Inc. is 001-41666.
What is the SIC code for CASI Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for CASI Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 203 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-08-16 08:30:21
Filing Documents
- tm2421221d1_6k.htm (6-K) — 11KB
- tm2421221d1_ex99-1.htm (EX-99.1) — 90KB
- tm2421221d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-090353.txt ( ) — 109KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei-Wu He Name: Wei-Wu He Title: Chairman & CEO Date: August 16, 2024